HealthScope BriefThe Startup Moving Blood Collection Into the Home
Inside SiPhox’s current mail-in service and its separate work on miniature laboratory technology.
HealthScope Brief Editors · Updated
EasyDraw collection at home. Image: SiPhox Health.
SiPhox’s blood-testing story has two parts: a mail-in collection service people can use now, and a separate effort to make laboratory technology small enough for a home device. Understanding the distinction makes the company easier to assess.
50,000+ people have used SiPhox for at-home blood testing.[5] The service starts with an upper-arm sample. The hardware project starts with photonics, the technology of manipulating light on a chip.[1][4]
A company with roots in MIT research
Michael Dubrovsky and Diedrik Vermeulen met while working in MIT’s research community. In a November 2024 profile, MIT News described their work on miniaturizing the optical components used in laboratory instruments.[1]
The company also attracted venture investment. Intel Capital announced a $27 million funding round in July 2023, led with Khosla Ventures.[2] That is part of the company’s history, rather than evidence that any particular test improves a health outcome.
What the current service involves
SiPhox’s present consumer service uses an EasyDraw collector on the upper arm. The sample is sent for laboratory analysis, and the results are made available through a dashboard. The company lists both focused and broader testing programs.[4]
For a user, the practical change is where collection happens. There is still a laboratory involved, and the measurements still need to be chosen for a reason. This is different from a device that analyzes a sample immediately in your home.
Why the hardware distinction matters
SiPhox describes SiPhox One as an investigational device. Its mission page distinguishes that development project from the mail-in testing service.[3]
Older reporting about the chip technology should therefore not be read as a description of the kit currently offered to consumers. Nor should anticipated capabilities or regulatory milestones be presented as completed product features.
A closer look at the user experience
When comparing the service with an in-person draw, the useful questions are ordinary ones: Can you follow the collection process? Does the panel contain the requested tests? How will the results reach the person helping interpret them?
SiPhox’s current process page shows the collector and explains the return and results steps.[4] Those details matter more to an order placed today than a prediction about what future hardware could make possible.
Keep the two timelines separate
The company’s research history explains the ambition behind its name. Its current service information explains what a customer can purchase. Reading both makes room for interest in the technology while keeping the immediate testing decision concrete.
Explore Longevity Essentials
Sources
- Bringing lab testing to the home — Zach Winn · MIT News · November 14, 2024
- Intel Capital and Khosla Ventures lead $27M investment in SiPhox Health — Intel Capital · July 19, 2023
- SiPhox One: investigational device and company mission — SiPhox Health · checked September 10, 2026
- How at-home collection and lab processing work — SiPhox Health · checked September 10, 2026
- SiPhox Health company profile and launch posts — Y Combinator · company-reported information
General health information, not medical advice. Discuss concerning results or persistent symptoms with a licensed clinician. Enable JavaScript to use the on-page quiz.